Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 148,813 shares of the biopharmaceutical company’s stock after buying an additional 29,474 shares during the period. Peregrine Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $6,116,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of RARE. Headlands Technologies LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $28,000. UMB Bank n.a. raised its position in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 622.3% during the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 865 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 400 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 3,182.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 1,623 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the transaction, the chief executive officer now owns 2,243,985 shares in the company, valued at approximately $112,580,727.45. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 9,806 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the completion of the sale, the executive vice president now directly owns 57,981 shares in the company, valued at approximately $2,609,145. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,127 shares of company stock worth $1,539,993. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded down $0.18 during trading hours on Friday, hitting $56.78. 754,442 shares of the stock were exchanged, compared to its average volume of 805,332. The company’s 50 day moving average is $47.29 and its 200 day moving average is $45.70. The firm has a market capitalization of $4.72 billion, a P/E ratio of -7.07 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a one year low of $31.52 and a one year high of $58.73.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.12. The firm had revenue of $147.03 million during the quarter, compared to analysts’ expectations of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The business’s quarterly revenue was up 35.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.25) EPS. Research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

RARE has been the topic of a number of research reports. Robert W. Baird boosted their target price on shares of Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday, May 31st. Canaccord Genuity Group reiterated a “buy” rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. The Goldman Sachs Group boosted their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a report on Friday, May 31st. Finally, Cantor Fitzgerald boosted their target price on shares of Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.